openPR Logo
Press release

Lawsuit filed for Investors in shares of Bayer Aktiengesellschaft (OTC: BAYRY)

07-24-2020 12:29 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A lawsuit was filed on behalf of investors in Bayer Aktiengesellschaft (OTC: BAYRY) shares over alleged securities laws violations

A lawsuit was filed on behalf of investors in Bayer Aktiengesellschaft (OTC: BAYRY) shares over alleged securities laws violations

An investor, who purchased shares of Bayer Aktiengesellschaft (OTC: BAYRY), filed a lawsuit in the U.S. over alleged violations of Federal Securities Laws by Bayer Aktiengesellschaft.

Investors, who purchased shares of Bayer Aktiengesellschaft (OTC: BAYRY), have certain options and for certain investors are short and strict deadlines running. Deadline: September 14, 2020. OTC: BAYRY investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

On May 23, 2016, Bayer announced that it had made an unsolicited all-cash offer to acquire Monsanto Company, a U.S. based provider of agricultural chemicals and other products.

On June 7, 2018, Bayer completed its acquisition of Monsanto for $63 billion in cash (the "Acquisition").

On August 10, 2018, a California state court jury in the first Roundup cancer case to proceed to trial found unanimously that Roundup was a "substantial factor" in causing the plaintiff to develop non-Hodgkin's lymphoma and that Monsanto knew, or should have known, the risks associated with exposure to the chemical and failed to warn of this severe health hazard. The jury also found that Monsanto acted with "malice or oppression" and should be punished for its conduct. Accordingly, the jury ordered Monsanto to pay $39 million in compensatory damages and $250 million in punitive damages.

On October 22, 2018, although the court in that case reduced the award of punitive damages from $250 million to $39 million, the court otherwise denied Monsanto's motion for judgment notwithstanding the verdict and Monsanto's motion for a new trial, and upheld the jury's verdict that the plaintiff's exposure to Roundup was a substantial factor in causing his cancer.
Then, on March 19, 2019, a jury in the first federal Roundup cancer lawsuit to proceed to trial issued a verdict on causation in phase one of the bifurcated trial, finding that plaintiff's "exposure to Roundup was a substantial factor in causing his non-Hodgkin's lymphoma."
On June 24, 2020, Bayer Aktiengesellschaft a series of agreements that will substantially resolve major outstanding Monsanto litigation, including U.S. Roundup™ product liability litigation, dicamba drift litigation and PCB water litigation. The main feature is the U.S. Roundup™ resolution that will bring closure to approximately 75% of the current Roundup™ litigation involving approximately 125,000 filed and unfiled claims overall. Bayer Aktiengesellschaft said it will make a payment of $8.8 billion to $9.6 billion to resolve the current Roundup™ litigation, including an allowance expected to cover unresolved claims, and $1.25 billion to support a separate class agreement to address potential future litigation.

According to the complaint the plaintiff alleges on behalf of purchasers of Bayer Aktiengesellschaft (OTC: BAYRY) common shares between May 23, 2016, and March 19, 2019, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between May 23, 2016, and March 19, 2019, the Defendants made false and misleading statements to investors, describing the Acquisition as "a compelling transaction for shareholders" that would create "significant value" by generating "stronger growth, better profitability, and a more resilient business profile" and "will translate into attractive financial benefits for Bayer and its shareholders."

The plaintiff alleges that the Defendants specifically downplayed the liability risks related to Monsanto's Roundup product, emphasizing that the Company conducted a "thorough analysis" during due diligence and "undertook appropriate due diligence of litigation and regulatory issues throughout the process" which led Bayer to finalize the Acquisition.

Those who purchased shares of Bayer Aktiengesellschaft (OTC: BAYRY) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lawsuit filed for Investors in shares of Bayer Aktiengesellschaft (OTC: BAYRY) here

News-ID: 2095908 • Views: 464

More Releases from Shareholders Foundation

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) Investor Alert: Investigation over pot …
An investigation was announced over potential breaches of fiduciary duties by certain directors at Vanda Pharmaceuticals Inc. (NASDAQ: VNDA. Investors who purchased shares of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) and currently hold any of those Vanda Pharmaceuticals Inc. (NASDAQ: VNDA shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Vanda Pharmaceuticals Inc. (NASDAQ: VNDA
Investigation announced for Long-Term Investors in shares of Milestone Pharmaceu …
Certain directors of Milestone Pharmaceuticals Inc. are under investigation over potential breaches of fiduciary duties. Investors who purchased shares of Milestone Pharmaceuticals Inc. (NASDAQ: MIST) and currently hold any of those NASDAQ: MIST shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Milestone Pharmaceuticals directors breached their fiduciary duties and caused damage to the
Investigation announced for Long-Term Investors in shares of iQIYI, Inc. (NASDAQ …
An investigation was announced for investors in shares of iQIYI, Inc. (NASDAQ: IQ) concerning potential breaches of fiduciary duties by certain directors and officers of iQIYI, Inc.. Investors who are current long term investors in iQIYI, Inc. (NASDAQ: IQ) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: IQ
Investigation announced for Investors in shares of Noble Energy, Inc. (NASDAQ: N …
An investigation was announced concerning whether the takeover of Noble Energy, Inc.is unfair to: NBL stockholders. Investors who purchased shares of Noble Energy, Inc. (NASDAQ: NBL) and currently hold any of those NASDAQ: NBL shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain officers and directors of Noble Energy, Inc. breached their fiduciary duties

All 5 Releases


More Releases for Bayer

Drug Delivery Market 2018 | Johnson, Bayer
Report Summary The Global Drug Delivery Market Size is primarily driven by the increasing demand for technological advanced products that are used for drug delivery, and increased number of chronic diseases in the increasing number of geriatric population. Drug delivery is referred as drug administration in the human body through injections or various other devices. Drug delivery devices are used to inject the therapeutic substances in the body with the help of
Bayer Crop Sciences Ltd
Bayer Crop Sciences Ltd Bayer Crop Sciences Ltd- Company Profile & Financial Analysis” contains in depth information and data about the company and its operations. You will find information on the business structure, areas of operation, products and services offered by the company. It also comprises SWOT analysis, key ratios, historical financial data and insider’s view on financial stability and industrial ranking with financial forecasts for two- year period. This report is
Permethrin Market 2017 - Bayer, Heranba, Tagros, Meghmani
Apex Research, recently published a detailed market research study focused on the "Permethrin Market" across the global, regional and country level. The report provides 360° analysis of "Permethrin Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Permethrin industry, and estimates the future trend of Permethrin market on the basis of this
Global Spirotetramat Market 2017 : Bayer CropScience
Top Manufacture Analysis Of Spirotetramat Market 2017 Includes Market outline, section by Application, Market by Region and Production, Revenue (Value), worth Trend by kind. The Markets And analysis study delivers necessary information and realistic data of the globe Spirotetramat market. The report presents a deep study of the market growth factors and drivers. In-depth analysis of the Spirotetramat Market limitations and thus the opportunities modify the user to create the
Automotive Plastics Market 2017- AkzoNobel, BASF, Bayer
Marketreports.biz, recently published a detailed market research study focused on the "Automotive Plastics Market" across the global, regional and country level. The report provides 360° analysis of "Automotive Plastics Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Automotive Plastics industry, and estimates the future trend of Automotive Plastics market on
Global Pharmerging Market Research Report 2017: Bayer
This report studies Pharmerging in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering AstraZeneca GlaxoSmithKline Pfizer Sanofi Novartis Abbott Laboratories Shire Bayer Biogen F. Hoffmann-La Roche Johnson & Johnson Mitsubishi Tanabe Pharma Novo Nordisk Sun Pharmaceutical Takeda Pharma Teva Pharmaceutical Industries To Get Sample Copy of Report visit @ http://www.qyresearchreports.com/sample/sample.php?rep_id=973660&type=E Market Segment by Regions, this report splits Global into several key Regions, with production,